- Home
- EEFT vs IONS Comparison
EEFT vs IONS Comparison
Compare EEFT & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEFT
- IONS
- Stock Information
- Founded
- EEFT 1994
- IONS 1989
- Country
- EEFT United States
- IONS United States
- Employees
- EEFT N/A
- IONS N/A
- Industry
- EEFT EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- EEFT Technology
- IONS Health Care
- Exchange
- EEFT Nasdaq
- IONS Nasdaq
- Market Cap
- EEFT 4.7B
- IONS 5.4B
- IPO Year
- EEFT 1997
- IONS 1991
- Fundamental
- Price
- EEFT $108.28
- IONS $33.51
- Analyst Decision
- EEFT Buy
- IONS Buy
- Analyst Count
- EEFT 7
- IONS 18
- Target Price
- EEFT $125.57
- IONS $57.41
- AVG Volume (30 Days)
- EEFT 400.3K
- IONS 1.5M
- Earning Date
- EEFT 07-17-2025
- IONS 04-30-2025
- Dividend Yield
- EEFT N/A
- IONS N/A
- EPS Growth
- EEFT 18.66
- IONS N/A
- EPS
- EEFT 6.80
- IONS N/A
- Revenue
- EEFT $4,048,300,000.00
- IONS $717,253,000.00
- Revenue This Year
- EEFT $10.43
- IONS $7.14
- Revenue Next Year
- EEFT $7.92
- IONS $18.89
- P/E Ratio
- EEFT $15.92
- IONS N/A
- Revenue Growth
- EEFT 7.73
- IONS N/A
- 52 Week Low
- EEFT $85.24
- IONS $23.95
- 52 Week High
- EEFT $117.66
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- EEFT 55.95
- IONS 56.80
- Support Level
- EEFT $104.14
- IONS $32.00
- Resistance Level
- EEFT $109.65
- IONS $33.65
- Average True Range (ATR)
- EEFT 2.31
- IONS 1.08
- MACD
- EEFT -0.36
- IONS -0.10
- Stochastic Oscillator
- EEFT 45.85
- IONS 55.72
About EEFT Euronet Worldwide Inc.
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.